Literature DB >> 14718257

5-Hydroxytryptamine is biotransformed by CYP2C9, 2C19 and 2B6 to hydroxylamine, which is converted into nitric oxide.

Caroline Fradette1, Nobuharu Yamaguchi, Patrick Du Souich.   

Abstract

There is circumstantial evidence suggesting that 5-hydroxytryptamine (5-HT) could be biotransformed by enzymatic systems other than monoamino oxidase A, and that the isoforms of cytochrome P450 may be a source of nitric oxide. This study aimed to assess whether cytochrome P450 contributes to 5-HT biotransformation, and to provide evidence that 5-HT metabolism generates nitric oxide. Addition of 5-HT to cultured hepatocytes yielded 5-hydroxyindol acetic acid, a formation modulated by cytochrome P450 enzyme inducers and inhibitors. Recombinant human CYP2B6, 2C9 and 2C19 biotransformed 5-HT in 5-hydroxyindol acetic acid, but not CYP1A2, 2D6 or 3A4. Cultured hepatocytes with 5-HT generated nitric oxide, the amount of which was altered by cytochrome P450 enzyme inducers and inhibitors. In the presence of CYP2B6, 2C9 and 2C19, 5-HT relaxed precontracted isolated aortic rings, with or without endothelium, an effect prevented by the addition of methylene blue and an inhibitor of catalase, but not by myoglobin. In the absence of catalase, hydroxylamine was always assayed as a byproduct of 5-HT metabolism. In conclusion, CYP2B6, 2C9 and 2C19 biotransform 5-HT, yielding hydroxylamine, which is converted to nitric oxide in the presence of catalase. British Journal of Pharmacology (2004) 141, 407-414. doi:10.1038/sj.bjp.0705632

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14718257      PMCID: PMC1574215          DOI: 10.1038/sj.bjp.0705632

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  52 in total

Review 1.  Nitric oxide pathway, Ca2+ and serotonin.

Authors:  G D'Andrea
Journal:  Cephalalgia       Date:  1999-11       Impact factor: 6.292

Review 2.  Nitric oxide as modulator of neuronal function.

Authors:  H Prast; A Philippu
Journal:  Prog Neurobiol       Date:  2001-05       Impact factor: 11.685

3.  Further evidence that 5-HT-induced relaxation of pig pulmonary artery is mediated by endothelial 5-HT(2B) receptors.

Authors:  E Glusa; H H Pertz
Journal:  Br J Pharmacol       Date:  2000-06       Impact factor: 8.739

4.  Does serotonin relax the rat anococcygeus muscle via 5-HT7 receptors?

Authors:  S Emre; S R Erdem; M Tuncer
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2000-08       Impact factor: 3.000

5.  Inhibition of cytochrome P450 2C9 activity in vitro by 5-hydroxytryptamine and adrenaline.

Authors:  G Gervasini; C Martínez; J A Agúndez; F J García-Gamito; J Benítez
Journal:  Pharmacogenetics       Date:  2001-02

6.  Relative contributions of CYP2C9 and 2C19 to phenytoin 4-hydroxylation in vitro: inhibition by sulfaphenazole, omeprazole, and ticlopidine.

Authors:  G M Giancarlo; K Venkatakrishnan; B W Granda; L L von Moltke; D J Greenblatt
Journal:  Eur J Clin Pharmacol       Date:  2001-04       Impact factor: 2.953

7.  The inhibitory effect of 3-amino-1,2,4-triazole on relaxation induced by hydroxylamine and sodium azide but not hydrogen peroxide or glyceryl trinitrate in rat aorta.

Authors:  K B Mian; W Martin
Journal:  Br J Pharmacol       Date:  1995-12       Impact factor: 8.739

8.  A nitric oxide synthase inhibitor reduces hyperphagia induced in rats by the 5-HT(1A) receptor agonist, 8-OH-DPAT, independently of hypothalamic serotonin metabolism.

Authors:  J Yamada; Y Sugimoto; M Kunitomo
Journal:  Eur J Pharmacol       Date:  2000-08-25       Impact factor: 4.432

9.  Nifedipine increases cytochrome P4502C expression and endothelium-derived hyperpolarizing factor-mediated responses in coronary arteries.

Authors:  B Fisslthaler; N Hinsch; T Chataigneau; R Popp; L Kiss; R Busse; I Fleming
Journal:  Hypertension       Date:  2000-08       Impact factor: 10.190

10.  Brain serotonin dysfunction accounts for aggression in male mice lacking neuronal nitric oxide synthase.

Authors:  S Chiavegatto; V L Dawson; L A Mamounas; V E Koliatsos; T M Dawson; R J Nelson
Journal:  Proc Natl Acad Sci U S A       Date:  2001-01-16       Impact factor: 11.205

View more
  8 in total

1.  Phenobarbital increases monkey in vivo nicotine disposition and induces liver and brain CYP2B6 protein.

Authors:  Anna M Lee; Sharon Miksys; Rachel F Tyndale
Journal:  Br J Pharmacol       Date:  2006-06-05       Impact factor: 8.739

2.  Brain drug-metabolizing cytochrome P450 enzymes are active in vivo, demonstrated by mechanism-based enzyme inhibition.

Authors:  Sharon Miksys; Rachel F Tyndale
Journal:  Neuropsychopharmacology       Date:  2008-07-30       Impact factor: 7.853

Review 3.  Redox control of asthma: molecular mechanisms and therapeutic opportunities.

Authors:  Suzy A A Comhair; Serpil C Erzurum
Journal:  Antioxid Redox Signal       Date:  2010-01       Impact factor: 8.401

Review 4.  Cytochrome P450-mediated drug metabolism in the brain.

Authors:  Sharon Miksys; Rachel F Tyndale
Journal:  J Psychiatry Neurosci       Date:  2013-05       Impact factor: 6.186

5.  Gene variants in CYP2C19 are associated with altered in vivo bupropion pharmacokinetics but not bupropion-assisted smoking cessation outcomes.

Authors:  Andy Z X Zhu; Qian Zhou; Lisa Sanderson Cox; Jasjit S Ahluwalia; Neal L Benowitz; Rachel F Tyndale
Journal:  Drug Metab Dispos       Date:  2014-09-03       Impact factor: 3.922

Review 6.  Do we need pharmacogenetics to personalize antidepressant therapy?

Authors:  Cristina Lanni; Marco Racchi; Stefano Govoni
Journal:  Cell Mol Life Sci       Date:  2012-12-28       Impact factor: 9.261

7.  Drug metabolism within the brain changes drug response: selective manipulation of brain CYP2B alters propofol effects.

Authors:  Jibran Y Khokhar; Rachel F Tyndale
Journal:  Neuropsychopharmacology       Date:  2010-11-24       Impact factor: 7.853

Review 8.  Molecular characterization of CYP2B6 substrates.

Authors:  Sean Ekins; Manisha Iyer; Matthew D Krasowski; Evan D Kharasch
Journal:  Curr Drug Metab       Date:  2008-06       Impact factor: 3.731

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.